Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug

 Pfizer (PFE, Financial) and Arvinas (ARVN) are advancing in the competitive field of breast cancer treatment. Despite encountering mixed outcomes in their Phase 3 trials, the investigational drug vepdegestrant has demonstrated significant potential in patients harboring specific mutations. These promising results position it as a competitor to existing therapies, offering enhanced progression-free survival rates. The companies are targeting a late 2025 timeframe to file a new drug application with the FDA.

https://www.gurufocus.com/news/2899952/pfizer-and-arvinas-plan-fda-submission-for-breast-cancer-drug